This can be absorbable such as vicryl or biologic mesh, non-absorbable such as polypropylene (PPE) or expanded polytetrafluoroethylene (ePTFE), or selleck inhibitor a Wittman patch. The material is initially applied loosely to allow for bowel expansion and prevent ACS. Serial examinations of the wound at the bedside or in the operating room must be done and the mesh is pleated or refastened to gradually pull the fascial edges together [47–49]. The primary benefit of these systems is their ability
to maintain and recover fascial domain. Drawbacks include damage to the fascia, inability to prevent adhesions and difficulty with fluid management. EC fistula rates vary with type of graft material; as high as 7-26% with non-absorbable mesh [42, 50–52], followed by 4.6-18% with absorbable mesh [49, 53, 54], and the Wittman patch which has the lowest reported rates of 0–4.2% [55–58]. Risk of ECF is reduced if omentum is interposed between the mesh and bowel [52]. Primary closure has been reported as late as >50 days after the initial damage control
operation [49]. ACS rates associated with interposition grafts are seldom sited in the literature; most that did reported no incidences [48, 53, 54]. Resuscitation The second stage Raf inhibitor of DCL is resuscitation focused on correction of physiologic derangements, acidosis, oxygen debt, coagulopathy and hypothermia [1]. Hemodynamic derangements due to hypovolemic shock should be reversed as quickly as possible with volume resuscitation. However, over use of crystalloids can result in third spacing BMS345541 mouse worsening bowel edema, anastomotic leaks, ACS and multi-organ failure [59, 60]. Accordingly, the use of massive transfusion protocols (MTP) has been recommended for DCL patients [60–62]. MTP’s advocate using blood transfusion earlier in resuscitation, using blood and blood products instead of crystalloid or colloid, and the infusion of red cells, plasma,
and platelets in a 1:1:1 ratio. There is evidence to suggest that MTP’s and use of 1:1:1 transfusion ratios results in lower overall fluid requirements, blood utilization, and possibly improved mortality in patients with massive blood loss, severe injury and severe physiological derangements, such as are encountered in DCL patients [63, 64]. In addition, ADAMTS5 fluid resuscitation should be guided by hemodynamic parameters such as stroke volume variance or pulse pressure differentials and central venous or left atrial pressures. Improved fluid management may decrease the incidence of ACS and promote early fascial closure [28, 65, 66]. There is also some evidence that the use of hypertonic fluids in the postoperative period may decrease time to primary closure and improve the primary closure rate [67]. Patients should be monitored for development of ACS and if exhibiting symptoms, the TAC should be removed and replaced with a looser device immediately [2].